Prana Biotechnology (PRAN +3.2%) moves up after being initiated at Burrill Institutional...

|About: Prana Biotechnology Ltd (PRAN)|By:, SA News Editor

Prana Biotechnology (PRAN +3.2%) moves up after being initiated at Burrill Institutional Research with an Outperform and a price target of $5 a share. Burrill cites the company's progress in developing technology for the treatment of neurodegenerative disorders. Yesterday PRAN announced that it's completed recruitment in its Phase IIa clinical trial using its experimental drug PBT2 for the treatment of patients with Huntington Disease.